Opinion: failed Lp(a)-lowering trial raises questions about the limits of precision preventive cardiology

Writing in *Stat News*, cardiologist Vishal Khetpal offers a commentary on the implications of the HORIZON and ZEUS trial results for pelacarsen, an RNA-targeting therapy developed to lower lipoprotein(a) — a heritable lipid fraction whose elevated levels have been robustly associated with cardiovascular disease risk through large-scale genetic studies.

Lipoprotein(a), or Lp(a), is predominantly genetically determined, largely through variants at the *LPA* gene locus, and elevated levels represent one of the cleaner examples of a causal, Mendelian-randomisation-supported cardiovascular risk factor. The failure of pelacarsen to demonstrate the expected reduction in hard cardiovascular outcomes in large trials has therefore prompted a broader reassessment of the precision-medicine paradigm in preventive cardiology, where genetic epidemiology had appeared to identify a tractable target.

Khetpal argues that the results illustrate that strong genetic epidemiological associations do not automatically translate into therapeutic benefit when the causal pathway is intervened upon pharmacologically, and that epidemiology and genetics of complex disease risk may currently be outpacing the therapeutic toolkit. The piece is framed as opinion and reflects one clinician-researcher's interpretation; it does not represent formal guidance from any professional body.

The commentary is relevant for researchers working at the intersection of statistical genetics, Mendelian randomisation, and clinical translation, and for educators using cardiovascular genetics as a teaching case for the pipeline from GWAS association to therapeutic target validation.